AGING ANALYTICS AGENCY

InvestTech Advanced Solutions

Healthcare Predictive Analytics Market Overview

Healthcare predictive analytics brings together health system data, along with digital tools to inform care delivery creating personalized healthcare to support health and wellness. Application of biomarkers has an enormous potential to bring the positive changes to the healthcare predictive analytics.

Market overview

Healthcare Predictive Analytics market is projected to grow at a rate of 28.9% in terms of value, from USD 3.74 Billion in 2019 to reach USD 28.77 Billion by 2027.

Healthcare Data Analytics companies secured almost $2.0 billion in venture capital funding in 2021 thereby showing the trend for future growth.



The scope of biomarkers application

- Enhancing Insurance Programs
- Creation of Platforms for Therapeutic Clinical Trials
- Broad Biomedical Implications: Oncology, Diabetics, Cardiovascular Pathologies
- Personal Lifestyle and Diet Recommendations
- Longevity Researches
- Diverse and Accessible Molecular Diagnostics Array

Healthcare Predictive Analytics Market Participants

Patients

Patient benefits can be in terms of providing improved care access and customized treatment to patients, enabling greater patient involvement

Payers

The basic objective, which can be achieved using healthcare predictive analytics is, “the right treatment at the right price”

Healthcare Providers

Healthcare providers can benefit in terms of optimized treatment protocols, innovative patient care services offering personalized care, and competitor benchmarking

R&D Centers

The predictive modeling approach can help accelerate the research process. Drug discovery and development of new therapies can be expedited using novel models along with analytical tools

Regulatory Bodies

Incorporation of predictive modeling lends several advantages to healthcare authorities, regulatory bodies, and various independent organizations

Investors

Investors can benefit from allocation the financial resources into research studies to develop medications to cater to the growing unmet clinical demand on a global level

AGING ANALYTICS AGENCY

InvestTech Advanced Solutions

Top 5 Prominent Biomarkers Companies

Edifice Health

Edifice Health is immunological health and personalized nutrition company offering a novel metric of inflammatory health. The company created the iAge test that measures immune health and immune age based on the largest human immunity and aging database and cutting-edge AI algorithms. The test measures such parameters as systemic chronic inflammation level, adaptive immune system health, inflammatory/immune age, as well as advise how to improve measured parameters.

Founders	David Furman, Mark Davis
Total Funding Amount	$13.5M
Funding Status	Early Stage Venture
Biomarker Type	General
Business Approach	Multiple
Type	Potential Target

TruDiagnostic

TruDiagnostic is a Health Data company which main specialization is epigenetics, particularly DNA methylation. They created a TruAge test that measures DNA methylation and provides other aging metrics, including telomere length, intrinsic and extrinsic age calculations, immune cell subset deconvolution, and the current pace of aging. The test requires only one drop of blood and provides the customer with biological age and specific health risks. Additionally, the customer gets a free 30-minute telehealth consultation to go over results and receive some personal health recommendations.

Founder	Ryan Smith
Funding	Not disclosed
Biomarker Type	General
Business Approach	Manufacturer
Type	Potential Target

Vocalis Health

Vocalis Health created a digital platform that uses vocal biomarkers to measure the severity or presence of a disease state. Their technology is empowered by Artificial Intelligence and based on the dataset in more than 250 thousand voice recordings. The voice sample is collected via a mobile app or web browser, and then patented Machine Learning and Deep Learning technology analyze voice recordings for insights regarding various health conditions. VocalisCheck detects Covid-19 vocal biomarker, and VocalisTrack detects shortness-of-breath vocal biomarker that is a sign of Chronic obstructive pulmonary disease.

Founder	Daniel Aronovich, Shady Hassan, Tal Wenderow
Total Funding Amount	$9M
Number of Founding Rounds	1
Biomarker Type	NeuroTech
Business Approach	Interface
Type	Potential Target

Altoida

Altoida created a precision neurology platform that provides accurate, sensitive, and efficient brain health measurement and early detection and prediction of neurocognitive disease. The platform is based on a 10-minute activity set that measures nearly 800 digital biomarkers across 11 neurocognitive domains. These biomarkers include evaluation of hands micromovements, eye movements, voice, etc. Then results are processed with cutting-edge Artificial Intelligent that predicts neurological diseases. The result is Altoida NMI, a validated brain health platform that can be used on IOS and Android devices outside of the clinic, with no additional hardware or training.

Founders	A.Locher, F.Wahle, I.Tarnanas, M.Bjgler, R.Fischer
Total Funding Amount	$7.5M
Biomarker Type	NeuroTech
Business Approach	Interface
Type	Potential Target

CYTOX Group

CYTOX Group provides non-invasive risk assessment and patient stratification tools for Alzheimer's disease and dementia. Cytox is commercially launching its tests in conjunction with Affymetrix to support Pharmaceutical and Biotechnology companies developing novel therapeutics. Cytox has two products. genoSCORE™-LAB is a CE-marked test that predicts the risk of an individual developing Alzheimer's disease. genoTOR™ characterises an individual's genetic profile linked to mTOR-regulated signalling pathways (pathways that affect the risk of Alzheimer's and dementia).

Founder	Zsuzsanna Nagy
Total Funding Amount	$12.4M
Funding Status	Early Stage Venture
Biomarker Type	General
Business Approach	Manufacturer
Type	Potential Target

AGING ANALYTICS AGENCY

InvestTech Advanced Solutions

Quant Biomarkers Company

In December 2021, Deep Knowledge Group has announced the launch of Quant Biomarkers company in Basel, Switzerland. The company is designed as a multivector accelerator and looks for engagement and cooperation from all types of investors.

Quant Biomarkers specialises in the quantitative assessment of Biomarkers of Human Longevity, the development of personalised biomarker panels of aging, and oncology, fields which target established Hallmarks of Aging. It also supports investment de-risking across various sectors, including R&D and clinical and health insurance. Quant Biomarkers is an AI and tech-powered platform that will further contribute to the creation of structured financial products and analytics linked to biological age. Its main goal is the synthesis and validation of a tangible, effective, and personalized assessment approach that supports interventions and Longevity Medicine therapeutic modalities.

The company will also serve as an incubator, IP accelerator, and investment vehicle for the Longevity Biomarkers sector, acquiring the most prospective start-ups, teams, and R&D facilities in the industry for the development of Longevity Preventive Medicine and Precision Health products as well as financial and analytical services.

If you are interested to join our venture, contact us at info@quant-biomarkers.com

The scope of our activities within the Longevity Biomarkers Industry is not limited to creation of the uniquely engineered Longevity-tied financial instruments. We set a goal to identify and assess various financial solutions that would be based on diseases-related biomarkers as well.

Towards a Sustainable Future in Healthcare and Economy



Longevity Risk Modelling